迦南科技(300412.SZ):擬由迦南比遜向比遜醫藥增資4200萬元 用於“醫藥研發服務平台升級擴建項目”
格隆匯12月28日丨迦南科技(300412.SZ)公佈,公司於2021年12月28日召開第五屆董事會第五次會議和第五屆監事會第五次會議審議通過了《關於使用募集資金對全資子公司增資暨全資子公司向全資孫公司增資的議案》,董事會同意使用募集資金4200萬元向全資子公司南京迦南比遜科技有限公司(“迦南比遜”)增資,並由迦南比遜向其全資子公司南京比遜醫藥科技有限公司(“比遜醫藥”)增資4200萬元,增資款用於實施募投項目“醫藥研發服務平台升級擴建項目”。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.